MEOW-1 Results: Okava Cat GLP-1 Trial Readout Tracker

Creator: Iacob Pastina
Published: 2026-05-02T00:00:00.000Z

MEOW-1 Results: Live Tracker

When Okava publishes the MEOW-1 cat GLP-1 trial readout this summer, we'll update this page with the full data within hours. Until then: here's what we're watching for.

6 min read·Updated August 2, 2026·By Iacob Pastina

Pre-readout, status checked July 22, 2026Still no published results. We checked Okava's press room directly today: the most recent release remains First Cat Dosed in MEOW-1 from December 3, 2025. Nothing has been posted since. The trial began December 2025 with at least 50 cats; the "results weeks away" framing that circulated earlier was wrong, because OKV-119 cats were only being dosed in mid-2026. That dosing status rests on the anchor and Okava's own trial listing; CNBC, Smithsonian, and ABC News covered the trial but none of them state when the cats were dosed. With a 3-month primary weight endpoint and an approximately 6-month full evaluation, topline data is now estimated for summer 2027, roughly twelve months out. We monitor Okava's press room, dvm360 trade press, and, because collaborator Vivani Medical is publicly traded, Vivani investor disclosures, since a material readout can surface in an investor filing before it reaches a press release.

MEOW-1 is the world's first clinical trial of a pet-specific GLP-1 receptor agonist. Whether it succeeds or fails defines the trajectory for the entire pet GLP-1 category. This page will update with the full data the day Okava publishes results.

The second readout almost nobody is watchingMEOW-1 is no longer the only feline GLP-1 result due this year. Akston Biosciences' AKS-562c is in a Cornell-run trial of client-owned cats, targeting 70 animals with an option to expand to 140, and Akston has said top-line results are expected later in 2026. That matters because the two programs are not the same bet: OKV-119 is a six-month implant, AKS-562c is a once-weekly injection. If one reads out well and the other does not, the difference tells you whether the obstacle is the molecule or the delivery route. Anyone treating MEOW-1 as a single yes-or-no verdict on pet GLP-1s is reading it wrong.

What Will Be Reported

Expected primary endpoints based on the published trial design:

•Body weight change at 3 months and 6 months versus baseline and versus control.
•Body Condition Score (BCS) change on the 9-point veterinary scale. The BCS shift is what veterinarians actually care about.
•Adverse event profile: nausea, vomiting, decreased appetite, hepatic enzyme elevation (ALT, ALP).
•Implant tolerability: local reactions at the implant site, infections, dropouts.
•Owner-reported quality of life measures.

The Three Outcome Scenarios

Scenario	Body weight Δ at 3mo	AE profile	Field response
Strong success	>8% loss vs control	Mild GI, no hepatic signal	Okava files FDA late 2026. Cat market launch 2027-2028. Industry incumbents (Zoetis, Boehringer, Merck Animal Health, Elanco) accelerate own programs. Investor sentiment for AXTN spikes.
Modest success	4-8% loss vs control	Acceptable, manageable	Okava runs confirmatory trial. FDA path to 2028. Market cap implications mixed: Akston AKS-562c readout becomes the deciding signal for the broader category.
Marginal	<4% loss vs control	Acceptable but underwhelming	Commercial viability questionable at $100/mo retail. Okava may pivot or consolidate. Akston Cornell readout becomes critical. Pet GLP-1 category reset to slower trajectory.
Failure / safety	No meaningful efficacy OR hepatic signal	Trial concerns	OKV-119 program likely shelved. Field resets to AKS-562c as only remaining feline candidate. Investor confidence in pet GLP-1 category drops. Dog programs delayed.

Why the Readout Matters Beyond Cats

MEOW-1 is the most-watched veterinary trial of 2026 because it sets three precedents simultaneously:

FDA-CVM precedent for novel-mechanism vet drugs. The agency's comfort with GLP-1 as an indication will inform how it treats subsequent feline and canine GLP-1 candidates.
Commercial template for vet biologics. Pricing, distribution (vet-prescribed vs telehealth), and adoption rate will anchor expectations for LOY-002, AKS-562c, and any future canine GLP-1.
Investor confidence for the category. A successful readout could trigger a wave of capital into veterinary biotech: potentially funding the canine GLP-1 program neither Okava nor Akston has formally announced yet.

Get the readout the day it landsJoin the trial alerts list: one email when Okava publishes MEOW-1 results. We'll publish the full data, the analysis, and the field implications here on this page within hours.

Pipeline updates

Get notified when pet GLP-1 medications arrive.

One email when there's real news: Okava MEOW-1 results, FDA filings, the first cat & dog GLP-1 launches. Nothing else.

We never share your email. Unsubscribe in one click. Powered by Resend.

Frequently Asked Questions

When will MEOW-1 results be published?+

Topline data is expected summer 2027. Earlier reporting put it at summer 2026, but cats were only being dosed in mid-2026, and the 3-month primary endpoint plus an approximately 6-month full evaluation pushes the readout about a year out. That summer-2027 estimate follows the trial's own design; CNBC's July 18, 2026 report covered the trial but did not state when Okava's cats were dosed.

Where will Okava publish the results?+

Likely channels: an Okava press release, a peer-reviewed journal submission (potentially JVIM or Veterinary Record), and trade press coverage (dvm360, Veterinary Practice News, Smithsonian which previously covered the trial start). Investor channels for Vivani Medical (Okava's implant manufacturing collaborator, publicly traded) may surface signals via SEC filings.

What's a clinically meaningful weight loss in cats?+

For overweight/obese cats, vets generally consider 4-8% body weight loss over 3 months as meaningful, with 8%+ as a strong signal. Anything below 3% over 3 months is commercially marginal. Within the range achievable through diet alone, which is cheaper and safer.

Can I enroll my cat in the MEOW-1 trial?+

Trial enrollment likely closed in late 2025 / early 2026. The trial enrolled at least 50 cats and is now in the data analysis phase. Future trials (potentially expanded cohort or follow-up studies) may open enrollment after the initial readout.

Veterinary disclaimer:This article is for informational purposes only and does not constitute veterinary advice. Always consult a licensed veterinarian before changing your pet's diet, exercise routine, or medication. Information is current as of the publication date but pet pharmaceutical and food formulation details may change.